BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yiu SPT, Dorothea M, Hui KF, Chiang AKS. Lytic Induction Therapy against Epstein-Barr Virus-Associated Malignancies: Past, Present, and Future. Cancers (Basel) 2020;12:E2142. [PMID: 32748879 DOI: 10.3390/cancers12082142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Stępień E, Strycharz-Dudziak M, Malm M, Drop B, Polz-Dacewicz M. Serum and Tissue Level of TLR9 in EBV-Associated Oropharyngeal Cancer. Cancers (Basel) 2021;13:3981. [PMID: 34439137 DOI: 10.3390/cancers13163981] [Reference Citation Analysis]
2 Yanagi Y, Watanabe T, Hara Y, Sato Y, Kimura H, Murata T. EBV Exploits RNA m6A Modification to Promote Cell Survival and Progeny Virus Production During Lytic Cycle. Front Microbiol 2022;13:870816. [DOI: 10.3389/fmicb.2022.870816] [Reference Citation Analysis]
3 Quaglia M, Merlotti G, De Andrea M, Borgogna C, Cantaluppi V. Viral Infections and Systemic Lupus Erythematosus: New Players in an Old Story. Viruses 2021;13:277. [PMID: 33670195 DOI: 10.3390/v13020277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Lee J, Stone J, Desai P, Kosowicz JG, Liu JO, Ambinder RF. Arsenicals, the Integrated Stress Response, and Epstein-Barr Virus Lytic Gene Expression. Viruses 2021;13:812. [PMID: 33946406 DOI: 10.3390/v13050812] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Murata T, Sugimoto A, Inagaki T, Yanagi Y, Watanabe T, Sato Y, Kimura H. Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation. Viruses 2021;13:2344. [PMID: 34960613 DOI: 10.3390/v13122344] [Reference Citation Analysis]
6 Yanagi Y, Hara Y, Mabuchi S, Watanabe T, Sato Y, Kimura H, Murata T. PD-L1 upregulation by lytic induction of Epstein-Barr Virus. Virology 2022. [DOI: 10.1016/j.virol.2022.01.006] [Reference Citation Analysis]